ArticleBMC cancer2026
MRI quantification of intratumoral heterogeneity for predicting HER2-positive status in breast cancer: a retrospective multicenter study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHER2 positive directly determines whether to use targeted drugs, but the existing methods are still lack of noninvasive methods. This study aims to predict HER2-positive status in breast cancer patients by quantifying Intratumoral heterogeneity (ITH) using pre-treatment MRI and to explore the association between ITH scores and HER2-positive response. MATERIALS AND
methodsA multicenter retrospective study enrolled breast cancer patients who underwent pretreatment MRI at two hospitals, regardless of molecular subtype. ITH scores were derived from MRI radiomic features. Pearson correlation analysis was used to assess the relationship between ITH scores and HER2 status. The predictive value of ITH scores and age for HER2 positivity was also evaluated. Subgroup analyses by age and hospital were conducted to validate the association between HER2 positivity and related factors.
resultsA total of 526 patients were included, with 294 from the first hospital and 232 from the second. The AUC for predicting HER2-positive status using ITH was 0.898, with a sensitivity of 0.827 and a specificity of 0.913. Additionally, an ITH + age combined model was constructed, which achieved an AUC of 0.898, sensitivity of 0.812, and specificity of 0.913 for HER2 positivity prediction in the validation set. Subgroup analysis revealed stable predictive efficacy across hospitals and improved discriminability for patients aged over 40.
conclusionsThe ITH score is significantly associated with HER2-positive status in breast cancer and has potential as a non-invasive biomarker for predicting HER2-positive status. As an adjunct to pathological examination, it may support clinical decision-making but is not intended to replace tissue biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.